story of the week
ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in CML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia
Leukemia 2022 Jul 28;[EPub Ahead of Print], L Schönfeld, J Rinke, A Hinze, SN Nagel, V Schäfer, T Schenk, C Fabisch, TH Brümmendorf, A Burchert, P le Coutre, SW Krause, S Saussele, F Safizadeh, M Pfirrmann, A Hochhaus, T ErnstFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.